TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04629144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab administered subcutaneously 200mg weekly from week 1 to week 24.~Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Both arms will have the same corticosteroid tapering scheme, with an initial dose of 30 mg/day. The following schedule of reduction of prednisone will apply to both groups as long as the disease is inactive:~* 30 mg/day week (W)0-W2,~* 20 mg/day W2-W4~* 15 mg/day W4-W6,~* 10 mg/day W6-W8,~* 5 mg/day W8-W10~Between W10-W12 the strategy for stopping glucocorticoids is left to the investigator's discretion.~Stopping glucocorticoid therapy at W12. At each step, the prednisone dose will be reduced only in the absence of signs of vasculitis activity.
Study: NCT05886075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type 1 (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT05934097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT596
Description: Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 (maximum dose 2 mg) intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 (maximum dose 2 mg) intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m\^2 IV infusion
Study: NCT05690022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: Patients will be recruited for a sleeve gastrectomy according to the guidelines of the National Institute of Health.
Study: NCT06443671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CapeOX
Description: Receiving CapeOX treatment for up to four cycles before surgery:~Capecitabine: 1000mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 130 mg/m2, intravenous drip for 0-2 hours, D1, Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib and Tislelizumab combined with mCapeOX
Description: Receiving Fruquintinib plus Tislelizumab combined with mCapeOX treatment for up to four cycles before surgery:~Fruquintinib: 3mg/d, QD, PO, Use for 2 weeks, stop for 1 week, Q3W; Tislelizumab: 200mg, D1, Intravenous infusion, Q3W; Capecitabine: 825mg/m2, BID, PO, D1-14, Q3W; Oxaliplatin: 100 mg/m2, intravenous drip for 0-2 hours, D1, Q3W.
Study: NCT05687942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBUILD
Description: 3.1.1. REBUILD is an investigational medical device provided as a sterile, single use set containing 10 suture Anchors and two non-implantable Carriers, with reusable stainless-steel instruments for deployment supplied separately.
Study: NCT06089876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRAVA mobile application
Description: The adolescents in the intervention group will use the STRAVA mobile application for a period of 10 weeks. To do so, they will follow the instructions provided by the researchers on the frequency of use, the distance to be covered and how to record it.
Study: NCT05585242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infertility ACTion Program
Description: Seven 15-minutes videos of Acceptance and commitment therapy adapted for women with infertility with assigned homework and summaries of the videos.
Study: NCT05162768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: 60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks
Study: NCT04803084

Intervention type: OTHER
Intervention: Tempus assay
Description: Blood collection

Intervention type: OTHER
Intervention: Advanced pathology 1
Description: Tissue procurement (from diagnostic biopsy)

Intervention type: OTHER
Intervention: Advanced pathology 2
Description: Tissue procurement (from research biopsy)
Study: NCT04677465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RheOx Bronchial Rheoplasty
Description: bronchial rheoplasty is a staged procedure wherein pulsed electric fields are delivered to the right lung in the first treatment visit, and then the left lung is treated approximately 1 month later.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: staged sham procedure wherein bronchoscopy is performed, the catheter is inserted into the right lung, but energy is not delivered; then the same steps are performed in the left lung approximately 1 month later (no energy is delivered to the patient)
Study: NCT06297564

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone primed endometrial protocol
Description: The cases were received soft progesterone capsules (brand name: Utrogestan, 100 mg, Laboratories Besins International, France) 100 mg and 150 IU of human menopausal gonadotropin (hMG) concomitantly from the menstrual cycle (MC) day 3 until the trigger day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone antagonist protocol
Description: The cases were received the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol consisting of HMG 150 IU's daily injection from MC 3 until the trigger day. GnRH-ant (Cetrotide, 0.25 mg, MerckSerono) was started when at least one of the following criteria were met: LH \>10 IU/L, the presence of at least one follicle with mean diameter \>14 mm, or serum E2 level \>600 pg/mL.
Study: NCT06483984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Respiratory support with a facemask connected to a ventilator through a heated humidifier. Ventilator will be set in the pressure support mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: Respiratory support with a facemask connected to a ventilator through a heated humidifier. Ventilator will be set in the pressure support mode.
Study: NCT06347627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3 (I x E x S x F)
Description: Experimental message: Individual x Effectiveness x Storytelling x Factual
Study: NCT06483984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Respiratory support with a facemask connected to a ventilator through a heated humidifier. Ventilator will be set in the pressure support mode.
Study: NCT06347627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 4 (O x E x S x F)
Description: Experimental message: Organization x Effectiveness x Storytelling x Factual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 5 (I x S x S x M)
Description: Experimental message: Individual x Safety x Storytelling x Misinformation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 6 (O x S x S x M)
Description: Experimental message: Organization x Safety x Storytelling x Misinformation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 7 (I x E x S x M)
Description: Experimental message: Individual x Effectiveness x Storytelling x Misinformation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 8 (O x E x S x M)
Description: Experimental message: Organization x Effectiveness x Storytelling x Misinformation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 9 (I x S x D x F)
Description: Experimental message: Individual x Safety x Scientific data x Factual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 10 (O x S x D x F)
Description: Experimental message: Organization x Safety x Scientific data x Factual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 11 (I x E x D x F)
Description: Experimental message: Individual x Effectiveness x Scientific data x Factual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 12 (O x E x D x F)
Description: Experimental message: Organization x Effectiveness x Scientific data x Factual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 13 (I x S x D x M)
Description: Experimental message: Individual x Safety x Scientific data x Misinformation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 14 (O x S x D x M)
Description: Experimental message: Organization x Safety x Scientific data x Misinformation
Study: NCT05402579

Intervention type: GENETIC
Intervention: Genomic analysis
Description: Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)

Intervention type: GENETIC
Intervention: Genomic analysis
Description: Genetic samples will be collected using a DNA saliva collection kit (Oragene: OG-510) and will be sent for genome-wide genotyping to The Centre for Applied Genomics in The Hospital for Sick Children (SickKids)
Study: NCT06614803

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation combined slow breathing
Description: The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear,the screen of the device displays slow breathing guidance video at 0.1Hz, while the device delivered stimulation during the 5 seconds of exhalation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation combined slow breathing
Description: The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear,the screen of the device displays slow breathing guidance video at 0.1Hz, while the device delivered stimulation during the 5 seconds of exhalation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: Without slow breathing guidance video on the stimulation device,the stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation
Description: Without slow breathing guidance video on the stimulation device,the stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear
Study: NCT06347627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 15 (I x E x D x M)
Description: Experimental message: Individual x Effectiveness x Scientific data x Misinformation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 16 (O x E x D x M)
Description: Experimental message: Organization x Effectiveness x Scientific data x Misinformation
Study: NCT05511935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: professional development training for CHWs on dental health (GRIN)
Description: multi module online training
Study: NCT06613386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The information-based discharge preparation service (IBDPS)
Description: The main modules of the IBDPS platform include:~* Establishing information records for infants and parents.~* Collaboratively identifying existing or potential caregiving challenges.~* Assessing parents' emotional and psychological states, providing support and intervention.~* Collaboratively establishing caregiving objectives with parents.~* Collaboratively formulating and executing caregiving plans.~* Assessing parental support resources, offering analysis, assistance, and necessary referrals.~* Conducting outcome assessments.
Study: NCT06614153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRG2010(I)
Description: HRG2010(I)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRG2010(II)
Description: HRG2010(II)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained-release Carbidopa/Levodopa
Description: Sustained-release Carbidopa/Levodopa
Study: NCT06006130

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires 11 minutes in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
Study: NCT06614452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-FNB
Description: Endoscopic ultrasound will be performed using a curvilinear array echoendoscope. FNB with 22G or 25G end-cutting needles will be performed. The size of the needles will be based on the personal choice of the endoscopist. Likewise, the sampling technique, whether using the slow-pull, the dry suction, or the wet suction, will be based on the physician's choice. Three passes will be performed as per current guidelines. Specimens will be collected in 3 vials to allow for analysis according to needle pass; one for the first pass, one for the second pass, and one for the third and any eventual subsequent passes.~The rapid-on site cytological evaluation (ROSE) will not be available in this study.
Study: NCT06294431

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 5
Description: Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 5.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
Study: NCT06229470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evoke Spinal Cord Stimulation (SCS) System
Description: A spinal cord stimulation (SCS) system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude.
Study: NCT06613711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnet System, DI Biofragmentable
Description: Anastomoses achieved by magnetic compression.
Study: NCT06615414

Intervention type: OTHER
Intervention: participants are not assigned an intervention as part of the study
Description: participants are not assigned an intervention as part of the study

Intervention type: OTHER
Intervention: participants are not assigned an intervention as part of the study
Description: participants are not assigned an intervention as part of the study
Study: NCT06528782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pecha Kucha method
Description: The Pecha Kucha method will be prepared in the form of a presentation consisting of 20 slides each shown for 20 seconds. The Pecha Kucha presentation lasts 6 minutes and 40 seconds, and most slides present only images. This method is planned to be used in breastfeeding education as it will be more memorable because it contains more visual, auditory and short information.
Study: NCT06294431

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 5.2 Usage
Description: Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 6
Description: Participants will use their Placebo Control Form 6 as directed for a period of 6 weeks.
Study: NCT06675175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4144
Description: Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally to randomized participants as per the arm they are assigned.
Study: NCT06688708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using vibrating foot orthosis with tactile stimulation
Description: Stimulating tactile sensation by using vibrating foot orthosis in conjunction with a random 0-100 Hz square wave pulse stimulus and pseudorandom white noise via a stochastic resonance approach.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Using vibrating foot orthosis without tactile stimulation
Description: Stimulating tactile sensation by using vibrating foot orthosis with only vibration 100 Hz freqency.
Study: NCT06294431

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 6.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 6.1 as directed for a period of 6 weeks.
Study: NCT06290193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution/ANH
Description: For participants randomized to ANH, the volume of blood to be removed will be calculated using an established formula, based on preoperative hemoglobin, target hemoglobin after hemodilution, and the patient's estimated blood volume.
Study: NCT06696937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: Tai chi is a practice that involves a series of slow gentle movements and physical postures, a meditative state of mind, and controlled breathing. Tai chi originated as an ancient martial art in China. Over the years, it has become more focused on health promotion and rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: full body vibrator
Description: Advocates say that as little as 15 minutes a day of whole-body vibration three times a week may aid weight loss, burn fat, improve flexibility, enhance blood flow, reduce muscle soreness after exercise, build strength and decrease the stress hormone cortisol.
Study: NCT06696742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Butyricum Tablets
Description: Gemcitabine and Cisplatin combined with Clostridium Butyricum Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Gemcitabine and Cisplatin
Study: NCT06696404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Lumbar Plexus and Sacral Plexus Block
Description: This intervention of Combined Lumbar Plexus and Sacral Plexus Block is assigned to Nerve block anesthesia group (NA group): A combined Lumbar Plexus Block (0.33% Ropivacaine 30ml) and Sacral Plexus Block (0.33% Ropivacaine 20ml) administered as a single injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iliac fascial block
Description: iliac fascial block administered as a single injection below the iliac fascial with 0.33% ropivacaine 30ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Spinal anesthesia was performed as a standard care of spinal anesthetic. The spinal puncture site is at L2-3 or L3-4. After the puncture needle reaches the subarachnoid space, 1% ropivacaine 0.8-2 ml, totaling 8-20mg, is injected. Depending on the center's practice, it may be replaced with an equivalent dose of bupivacaine .
Study: NCT05381753

Intervention type: DRUG
Intervention: Avapritinib
Description: Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.

Intervention type: DRUG
Intervention: Avapritinib
Description: Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.

Intervention type: DRUG
Intervention: Avapritinib
Description: Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.

Intervention type: DRUG
Intervention: Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )
Description: Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
Study: NCT05988892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Use Exercise to increase physical activity (PA), as measured by cardiovascular endurance, muscular strength, and balance in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address and to increase quality of life (QOL), as measured by physical functioning and fatigue, in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address.